SUMMARY The effect of auranofin on human neutrophil (PMN) 5-lipoxygenase activity and leucotriene B4 (LTB4) chemotaxis was investigated. [1-14C]Arachidonic acid was incorporated into the purified cells until steady state conditions were obtained. After preincubations with serial dilutions of auranofin arachidonic acid release and metabolism were stimulated with calcium ionophore A23187. The radioactive eicosanoids released were extracted and separated by thin layer chromatography, followed by autoradiography and quantitative laser densitometry. Chemotaxis of PMNs towards LTB4 was measured in a modified Boyden chamber. Auranofin showed dose dependent inhibition of both the 5-lipoxygenase pathway (IC50 17-4x 10-6 moll) and of chemotaxis (IC50 45 x 10-6 mol/1). The release of arachidonic acid from phospholipids was unaffected in the concentration range tested (1-1000 [tmol/1). Inhibition of both neutrophil motility and cellular synthesis of proinflammatory eicosanoids may thus contribute to the beneficial clinical effects of auranofin in rheumatoid arthritis.
Extracellular fluid containing radiolabelled metabolites was prepared by instantaneous removal of the cells by centrifugation (8000 g, one minute) through dibuthyl phthalate:dinonyl phthalate 3:1 (density 1*033 g/ml) before extraction of eicosanoids. '6 The radioactive metabolites were then separated by thin layer chromatography and measured by autoradiography and laser densitometry as previously described. 16 Fractions more lipophilic than arachidonic acid were not included in the calculations.
Identification of arachidonic acid and metabolites was carried out with cochromatography using pure standards (Paesel GmbH, Frankfurt am Main, FRG), and evaluation of specific activities by high pressure liquid chromatography has been described in detail previously. ' In a separate series of six experiments [1- 14C]arachidonic acid labelled PMNs were incubated with auranofin (31 gmol/l) for 15 minutes. One half of the aliquots was then challenged with A23187, whereas the other half was washed three times in Gey's medium before challenge. The percentage viability of the PMNs was assessed before and after the incubation.
CHEMOTAXIS OF NEUTROPHILS
Cells (2x106/ml) were added to the cellular compartment of modified Boyden chambers and migration proceeded in 3 im pore size filters (Sartorius Inc, Gottingen, FRG) for 45 minutes at 37oC.ll An optimal concentration of LTB4 (10 nmol/l), which earlier had been shown to be a potent chemoattractant, was chosen as activating agent. ,mol/l (range 12.3-23-8) (Fig. 1) .
Auranofin did not inhibit the arachidonic acid release from phospholipids, indicating that it did not have a steroid-like effect on the phospholipase system ( Table 1 ). The spontaneous release during control conditions was 1-7x 102 Bq/ml (1-2-2-3) .
The established lipoxygenase inhibitor nordihydroguaiaretic acid (10 gmol/1) included to validate the assay nearly abolished (>95% inhibition) the formation of the two 5-lipoxygenase metabolites, LTB4 and 5-HETE (p<O0O1). The influence of auranofin on neutrophil chemoInhibition of human neutrophils by auranofin 137 taxis has earlier been studied using the agarose technique, and it was found that PMNs preincubated with auranofin migrated a shorter distance than controls when stimulated with serum or bacterial factors-that is, cytotoxins with different nonspecific receptors on cell surfaces.14 The present study using the highly purified eicosanoid LTB4, activating PMNs through specific surface receptors,29 gave an IC50 value of 45 jmol/l with auranofin, again a value within the therapeutic range of auranofin concentrations.
In summary, the present results suggest that locally recruited PMNs may be inhibited by auranofin, leading to a minimised production of tissue destructive and proinflammatory mediators, such as LTB4 and 5-HETE. Furthermore, auranofin may reduce the migration of PMNs from circulating blood to the affected joints. Thus the inflammation may be further reduced by auranofin because PMNs apart from producing inflammatory active eicosanoids also have the potential for release of tissue destructive oxygen free radicals. 
